Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] ISU PETASYS (007660) -(Correction) Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2024-10-14 Semiconductors
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Supply Constraints · Memory Pricing · Earnings Growth / 2026-05-21 RESEARCH
  • [Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the U.S. / 2024-08-14 Disclosures
  • [Disclosure] PSK Holdings (031980) – Investor Relations (IR) Host / 2026-02-19 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Execution of Sales / Supply Contract / 2026-06-19 Disclosures
  • [Disclosure] KEPCO (015760 / KEP) – Decision to Convene General Meeting of Shareholders / 2026-05-06 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Investor Relations (IR) Holding / 2025-05-09 Disclosures
  • [Disclosure] ALTEOGEN (196170) – Trading Suspension and Resumption of Stock Futures and Options / 2026-07-16 Disclosures

[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2024-11-21

Posted on November 21, 2024August 6, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Celltrion decided to acquire approximately KRW 100 billion (583,431 common shares) worth of its own shares on the open market to stabilize its stock price and enhance shareholder value. The acquisition period runs from November 22, 2024, to February 21, 2025.

📊 Key Disclosure Content & Financial Highlights

  1. Overview
  • Company: Celltrion, Inc. (Stock Code: 068270)
  • Disclosure Type: Major Matters Report (Treasury Share Acquisition Decision)
  • Decision Date: November 21, 2024
  1. Treasury Share Acquisition Details
  • Shares to acquire: 583,431 common shares
  • Expected Acquisition Amount: KRW 100,000,073,400 (approx. KRW 100 billion)
  • Expected Acquisition Period: November 22, 2024 – February 21, 2025
  • Purpose: Stock price stabilization and enhancement of shareholder value
  • Method: On-market purchase via the KOSPI market
  • Entrusted Brokers: NH Investment & Securities, Meritz Securities
  • Daily Purchase Order Limit: 128,986 common shares
  1. Treasury Shares Held Prior to Acquisition (As of November 21, 2024)
  • Acquisition within Distributable Earnings Limit: 6,629,434 common shares (3.1%)
  • Other Acquisitions: 4,834,777 common shares (2.2%)
  • Total Treasury Shares Held Prior to Acquisition: 11,464,211 common shares (5.3%)
  1. Key Details & Investment Risks
  • The expected acquisition amount is calculated based on the closing price on the business day prior to the board resolution (November 20, 2024: KRW 171,400), and actual acquisition amounts may vary depending on stock price fluctuations.
  • Expected holding period is at least 6 months from the final acquisition date.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Treasury Share Open-Market Purchases and Final Execution Results

This disclosure serves as official notification regarding Celltrion’s board decision to purchase approximately KRW 100 billion of its own shares on the open market. Tracking whether the planned share purchases are executed accordingly during the specified period (November 22, 2024 – February 21, 2025) and reviewing the final acquisition report is important. Relevant updates can be confirmed through future disclosures or official IR materials.

📢 Disclaimer & Source Notice

Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) – Domestic (MFDS) Marketing Authorization for Stoboclo & Osenvelt (CT-P41, Prolia & Xgeva Biosimilar) / 2024-11-21
Next Post: [Disclosure] SK Square (402340) – Corporate Value-Up Plan / 2024-11-21

Related Posts

  • [Disclosure] Jeju Semiconductor (080220) – Decision on Issuance of Convertible Bonds (8th Series) / 2025-02-20 Semiconductors
  • [Disclosure] Samsung Biologics (207940) – Outlook on Operating Results Based on Consolidated Financial Statements (Fair Disclosure) / 2025-01-22 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Holding / 2024-05-03 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Subscription Results for Paid-in Capital Increase / 2025-07-08 Disclosures
  • [Disclosure] PSK Holdings (031980) – (Correction) New Facility Investment / 2024-02-29 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-11-24 Disclosures
  • [Disclosure] ALTEOGEN (196170) – Change of Market Division / 2025-04-30 Disclosures
  • [Disclosure] Hana Micron (067310) – Report on Reasons for Holding Shareholder Meeting on Concentrated Dates / 2025-03-11 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Decision on Convening General Meeting of Shareholders / 2026-08-07 Disclosures
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | 4Q25 Preview · AI Server Expansion · Core & New Business Momentum / 2025-12-26 RESEARCH
  • [Disclosure] Hanwha Ocean (042660) – Decision on Rights Issue (Major Management Matters of Subsidiary) / 2025-09-01 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Ex-Dividend Reference Price Notice for Interim (Quarterly) Dividend (Hyundai Motor 1st Preferred Stock) / 2025-08-27 Disclosures
  • [Disclosure] Jusung Engineering (036930) – Suspension of Trading (Changes or Cancellation of Electronic Registration for Stock Consolidation, Split, Etc.) / 2024-10-25 Semiconductors
  • [Disclosure] Celltrion (068270) – Application for Extension of Marketing Authorization for CT-P6 SC (Herzuma Subcutaneous) in Europe / 2026-04-30 Disclosures

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme